Latest news with #anti-obesity

South China Morning Post

China GLP-1 drug study suggests slim chance weight stays off after treatment

A Chinese analysis of prescription anti-obesity medications has added to evidence that people who use popular GLP-1 drugs such as Ozempic to shed pounds face the prospect of 'significant' weight rebound once they stop using them – challenges similar to those presented by more traditional slimming strategies. Patients saw 'significant weight' return eight weeks after anti-obesity medications (AOMs) were stopped, which continued after 20 weeks, the team from Peking University People's Hospital wrote in an article published in the peer-reviewed journal BMC Medicine on Tuesday. 'Weight regain is common in various weight-loss strategies and it is necessary to establish long-term anti-obesity treatment in clinical practice,' the researchers said. Worldwide, 2½ billion adults were overweight in 2022 and 890 million of them were obese, according to the World Health Organization 01:20 China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk China approves popular weight-loss drug Wegovy produced by Danish firm Novo Nordisk